[CLCD] CoLucid Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 37.9 Change: 1.65 (4.55%)
Ext. hours: Change: 0 (0%)

chart CLCD

Refresh chart

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities36.16 M Cash From Investing Activities Cash From Operating Activities-1.75 M Gross Profit
Net Profit-2.8 M Operating Profit-2.81 M Total Assets35.42 M Total Current Assets34.83 M
Total Current Liabilities1.63 M Total Debt Total Liabilities3.13 M Total Revenue
Technical Data
High 52 week46.53 Low 52 week5.38 Last close46.53 Last change0%
RSI60.87 Average true range0.07 Beta1.15 Volume373.25 K
Simple moving average 20 days0.16% Simple moving average 50 days10.87% Simple moving average 200 days81.4%
Performance Data
Performance Week0.05% Performance Month0.49% Performance Quart37.24% Performance Half390.25%
Performance Year661.46% Performance Year-to-date27.82% Volatility daily0.11% Volatility weekly0.24%
Volatility monthly0.49% Volatility yearly1.7% Relative Volume231.91% Average Volume528.18 K
New High New Low

News

2017-03-01 16:50:57 | COLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delis

2017-03-01 08:45:00 | Lilly Completes Acquisition of CoLucid Pharmaceuticals

2017-02-02 13:46:00 | INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders

2017-01-31 17:40:00 | Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. CLCD on Behalf of Stockholders and Encourages Investors to Contact the Firm

2017-01-31 16:38:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD

2017-01-30 17:19:00 | INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

2017-01-27 11:21:00 | INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD

2017-01-23 17:03:36 | Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset

2017-01-23 17:03:36 | Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset

2017-01-23 15:34:00 | SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

2017-01-20 18:05:00 | SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid Pharmaceuticals, Inc. -CLCD

2017-01-20 16:17:00 | COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. CLCD Over the Proposed Sale of the Company to Eli Lilly and Company

2017-01-19 15:54:00 | Robbins Arroyo LLP: Acquisition of CoLucid Pharmaceuticals, Inc. CLCD by Eli Lilly and Company LLY May Not Be in Shareholders' Best Interests

2017-01-19 14:42:10 | Here's Why CoLucid Pharmaceuticals Inc Popped Yesterday

2017-01-19 14:42:10 | Here's Why CoLucid Pharmaceuticals Inc Popped Yesterday

2017-01-19 13:40:36 | Here’s What You Need To Know About The Eli Lilly And Co LLY And CoLucid Pharmaceuticals Inc CLCD Deal

2017-01-19 09:41:03 | Eli Lilly and Company -- Moody's: Eli Lilly and Company's acquisition of pipeline-stage asset is credit negative

2017-01-19 08:42:01 | Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout

2017-01-19 08:15:00 | Blog Coverage Eli Lilly Announced Acquisition of CoLucid; Adds Lasmiditan to the Pain Management Portfolio

2017-01-19 00:29:22 | [$$] Overheard

2017-01-19 00:29:16 | Business Watch

2017-01-18 22:17:36 | [$$] Overheard

2017-01-18 18:06:05 | Why Fastenal, Mead Johnson Nutrition, and CoLucid Pharmaceuticals Jumped Today

2017-01-18 16:19:24 | Lilly Regains Key Migraine Drug With $960 Million CoLucid Acquisition

2017-01-18 15:31:00 | Harwood Feffer LLP Announces Investigation of CoLucid Pharmaceuticals, Inc.

2017-01-18 13:47:00 | Must-Know Tricks On Trading Goldman Sachs, Ford and Other Very Active Stocks

2017-01-18 12:46:00 | COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Eli Lilly and Company May be Unfair to Shareholders

2017-01-18 12:01:00 | COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

2017-01-18 11:47:00 | Eli Lilly Acquires CoLucid for $46.50 Per Share

2017-01-18 11:05:11 | Wednesday’s Top Biopharma Winners

2017-01-18 10:17:33 | Eli Lilly's Pricey Headache

2017-01-18 09:21:00 | Stock Futures Inch Higher as Citigroup, Goldman Sachs Get Trading Boost

2017-01-18 09:13:00 | Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

2017-01-18 08:25:19 | COLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or

2017-01-18 07:59:00 | CoLucid CLCD Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of CoLucid Pharmaceuticals, Inc.; Is $46.50 a Fair Price?

2017-01-18 07:53:00 | Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

2017-01-18 07:40:36 | What Eli Lilly Gets With CoLucid Acquisition

2017-01-15 07:42:10 | The 10 Best Stocks in the Nasdaq in 2016

2016-12-30 14:23:00 | Biotech's Top 3 Stock Losers, and Winners, in 2016

2016-12-23 09:30:02 | The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen

2016-12-22 09:28:02 | 4 Biotech Stocks that More than Doubled in 2016

2016-12-19 12:48:05 | Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?

2016-12-15 11:58:59 | Coverage initiated on CoLucid Pharmaceuticals by Barclays

2016-12-15 10:35:47 | CoLucid Pharmaceuticals, Inc. :CLCD-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016

2016-12-09 11:27:53 | CoLucid Pharmaceuticals Inc CLCD Draws Hedge Funds’ Attention

2016-12-02 15:46:41 | 3 Small-Cap Biotech Stocks That Could Double in 2017

2016-11-30 10:02:23 | The 5 Best Biotech Stocks of 2016

2016-11-28 13:59:27 | CoLucid Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference

2016-11-22 08:44:01 | CoLucid CLCD: Strong Industry, Solid Earnings Estimate Revisions

2016-11-17 13:04:13 | COLUCID PHARMACEUTICALS, INC. Financials